DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Intervention: Dexamethasone 0.1% ophthalmic suspension (Drug); Olopatadine hydrochloride 0.1% ophthalmic solution (Drug); Inactive ingredients, used as placebo (Other)

Phase: Phase 4

Status: Completed

Sponsored by: Alcon Research


The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

Clinical Details

Official title: A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex (0.1% Dexamethasone) Ophthalmic Suspension and Patanol (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic

Primary outcome:

Mean Change From Baseline in Staff-Assessed Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)], Maxidex and Placebo

Mean Change From Baseline Patient-Assessed Ocular Itching, Area Under the Curve From Time Zero to Hour 3 [AUC (0-3)], Patanol and Placebo

Detailed description: This study consisted of 6 visits. Visit 1 was the Medical Screening Visit (skin prick test). Visit 2 and Visit 3 consisted of 2 consecutive EEC Visits (3 hours in the EEC followed by 7 hours in the Clinic, 10 hours total, each visit) followed by 7 days of wash-out. Visit 2 and Visit 3 occurred prior to dispense and the measures obtained during these visits were used as baseline. At Visit 4 patients were randomized and dispensed the assigned study medication for 7 days of at-home dosing. Visit 5 (Day 8 of treatment) and Visit 6 (Day 9 of treatment) consisted of 2 additional consecutive EEC Visits (3 hours in the EEC followed by 7 hours in the clinic, 10 hours total, each visit). During each EEC visit, patients were exposed to either ragweed or cat allergen, depending on their skin prick test results. Of the 180 participants enrolled, 170 received at least one dose of study treatment and were randomized to one of the three study treatments.


Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Both.


Inclusion Criteria:

- At least 1 year history of allergic conjunctivitis.

- Ability to self administer ophthalmic drops.

- Ability to avoid use of disallowed medications during the entire study period and

specified period prior to visit 1.

- Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

- Presence of any ocular infection.

- Confirmed diagnosis of dry eye.

- Presence of glaucoma or ocular hypertension.

- Moderate to severe asthma.

- Any severe, unstable, or uncontrolled systemic disease.

- Other protocol-defined exclusion criteria may apply.

Locations and Contacts

Contact Alcon Call Center For Trial Locations, Fort Worth, Texas 76134, United States
Additional Information

Starting date: March 2010
Last updated: February 27, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017